26085 Key efficacy and safety of apremilast in patients with mild to moderate plaque psoriasis in the phase 3 ADVANCE trial
Duffin K, Gold L, Leonardi C, Pariser D, Green L, Sofen H, Strober B, Chen M, Wang A, Papp K. 26085 Key efficacy and safety of apremilast in patients with mild to moderate plaque psoriasis in the phase 3 ADVANCE trial. Journal Of The American Academy Of Dermatology 2021, 85: ab83. DOI: 10.1016/j.jaad.2021.06.356.Peer-Reviewed Original Research